 | • レポートコード：MRC2-11QY12167 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はC型肝炎治療薬のグローバル市場について調査・分析したレポートです。種類別（抗ウイルス剤、免疫調節剤、その他）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別C型肝炎治療薬の競争状況、市場シェア ・世界のC型肝炎治療薬市場：種類別市場規模 2015年-2020年（抗ウイルス剤、免疫調節剤、その他） ・世界のC型肝炎治療薬市場：種類別市場規模予測 2021年-2026年（抗ウイルス剤、免疫調節剤、その他） ・世界のC型肝炎治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック） ・世界のC型肝炎治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック） ・北米のC型肝炎治療薬市場分析：米国、カナダ ・ヨーロッパのC型肝炎治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのC型肝炎治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のC型肝炎治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのC型肝炎治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Gilead sciences、Abbvi、Johnson & Johnson、Merck、Glaxosmithkline、Novartis、Bristol-Myers Squibb、Roche ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc.
Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepatitis C is caused by hepatitis C virus and affects between 130–150 million people globally every year of which approximately 700 000 people die from hepatitis C-related liver diseases. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.
Market Analysis and Insights: Global Hepatitis C Drugs Market
The global Hepatitis C Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hepatitis C Drugs Scope and Market Size
Hepatitis C Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hepatitis C Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Gilead sciences
Abbvi
Johnson & Johnson
Merck
Glaxosmithkline
Novartis
Bristol-Myers Squibb
Roche
Market segment by Type, the product can be split into
Anti-Viral
Immuno-modulators
Others
Market segment by Application, split into
Hospitals
Clinics
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hepatitis C Drugs Revenue
1.4 Market by Type
1.4.1 Global Hepatitis C Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Anti-Viral
1.4.3 Immuno-modulators
1.4.4 Others
1.5 Market by Application
1.5.1 Global Hepatitis C Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Hepatitis C Drugs Market Perspective (2015-2026)
2.2 Global Hepatitis C Drugs Growth Trends by Regions
2.2.1 Hepatitis C Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hepatitis C Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Hepatitis C Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hepatitis C Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Hepatitis C Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Hepatitis C Drugs Players by Market Size
3.1.1 Global Top Hepatitis C Drugs Players by Revenue (2015-2020)
3.1.2 Global Hepatitis C Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Hepatitis C Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hepatitis C Drugs Market Concentration Ratio
3.2.1 Global Hepatitis C Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hepatitis C Drugs Revenue in 2019
3.3 Hepatitis C Drugs Key Players Head office and Area Served
3.4 Key Players Hepatitis C Drugs Product Solution and Service
3.5 Date of Enter into Hepatitis C Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hepatitis C Drugs Historic Market Size by Type (2015-2020)
4.2 Global Hepatitis C Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Hepatitis C Drugs Market Size by Application (2015-2020)
5.2 Global Hepatitis C Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hepatitis C Drugs Market Size (2015-2020)
6.2 Hepatitis C Drugs Key Players in North America (2019-2020)
6.3 North America Hepatitis C Drugs Market Size by Type (2015-2020)
6.4 North America Hepatitis C Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Hepatitis C Drugs Market Size (2015-2020)
7.2 Hepatitis C Drugs Key Players in Europe (2019-2020)
7.3 Europe Hepatitis C Drugs Market Size by Type (2015-2020)
7.4 Europe Hepatitis C Drugs Market Size by Application (2015-2020)
8 China
8.1 China Hepatitis C Drugs Market Size (2015-2020)
8.2 Hepatitis C Drugs Key Players in China (2019-2020)
8.3 China Hepatitis C Drugs Market Size by Type (2015-2020)
8.4 China Hepatitis C Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Hepatitis C Drugs Market Size (2015-2020)
9.2 Hepatitis C Drugs Key Players in Japan (2019-2020)
9.3 Japan Hepatitis C Drugs Market Size by Type (2015-2020)
9.4 Japan Hepatitis C Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Hepatitis C Drugs Market Size (2015-2020)
10.2 Hepatitis C Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hepatitis C Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Hepatitis C Drugs Market Size by Application (2015-2020)
11 India
11.1 India Hepatitis C Drugs Market Size (2015-2020)
11.2 Hepatitis C Drugs Key Players in India (2019-2020)
11.3 India Hepatitis C Drugs Market Size by Type (2015-2020)
11.4 India Hepatitis C Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Hepatitis C Drugs Market Size (2015-2020)
12.2 Hepatitis C Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Hepatitis C Drugs Market Size by Type (2015-2020)
12.4 Central & South America Hepatitis C Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Gilead sciences
13.1.1 Gilead sciences Company Details
13.1.2 Gilead sciences Business Overview
13.1.3 Gilead sciences Hepatitis C Drugs Introduction
13.1.4 Gilead sciences Revenue in Hepatitis C Drugs Business (2015-2020))
13.1.5 Gilead sciences Recent Development
13.2 Abbvi
13.2.1 Abbvi Company Details
13.2.2 Abbvi Business Overview
13.2.3 Abbvi Hepatitis C Drugs Introduction
13.2.4 Abbvi Revenue in Hepatitis C Drugs Business (2015-2020)
13.2.5 Abbvi Recent Development
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Details
13.3.2 Johnson & Johnson Business Overview
13.3.3 Johnson & Johnson Hepatitis C Drugs Introduction
13.3.4 Johnson & Johnson Revenue in Hepatitis C Drugs Business (2015-2020)
13.3.5 Johnson & Johnson Recent Development
13.4 Merck
13.4.1 Merck Company Details
13.4.2 Merck Business Overview
13.4.3 Merck Hepatitis C Drugs Introduction
13.4.4 Merck Revenue in Hepatitis C Drugs Business (2015-2020)
13.4.5 Merck Recent Development
13.5 Glaxosmithkline
13.5.1 Glaxosmithkline Company Details
13.5.2 Glaxosmithkline Business Overview
13.5.3 Glaxosmithkline Hepatitis C Drugs Introduction
13.5.4 Glaxosmithkline Revenue in Hepatitis C Drugs Business (2015-2020)
13.5.5 Glaxosmithkline Recent Development
13.6 Novartis
13.6.1 Novartis Company Details
13.6.2 Novartis Business Overview
13.6.3 Novartis Hepatitis C Drugs Introduction
13.6.4 Novartis Revenue in Hepatitis C Drugs Business (2015-2020)
13.6.5 Novartis Recent Development
13.7 Bristol-Myers Squibb
13.7.1 Bristol-Myers Squibb Company Details
13.7.2 Bristol-Myers Squibb Business Overview
13.7.3 Bristol-Myers Squibb Hepatitis C Drugs Introduction
13.7.4 Bristol-Myers Squibb Revenue in Hepatitis C Drugs Business (2015-2020)
13.7.5 Bristol-Myers Squibb Recent Development
13.8 Roche
13.8.1 Roche Company Details
13.8.2 Roche Business Overview
13.8.3 Roche Hepatitis C Drugs Introduction
13.8.4 Roche Revenue in Hepatitis C Drugs Business (2015-2020)
13.8.5 Roche Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Hepatitis C Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Hepatitis C Drugs Revenue
Table 3. Ranking of Global Top Hepatitis C Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hepatitis C Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Anti-Viral
Table 6. Key Players of Immuno-modulators
Table 7. Key Players of Others
Table 8. Global Hepatitis C Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Hepatitis C Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Hepatitis C Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Hepatitis C Drugs Market Share by Regions (2015-2020)
Table 12. Global Hepatitis C Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Hepatitis C Drugs Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Hepatitis C Drugs Market Growth Strategy
Table 18. Main Points Interviewed from Key Hepatitis C Drugs Players
Table 19. Global Hepatitis C Drugs Revenue by Players (2015-2020) (Million US$)
Table 20. Global Hepatitis C Drugs Market Share by Players (2015-2020)
Table 21. Global Top Hepatitis C Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatitis C Drugs as of 2019)
Table 22. Global Hepatitis C Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Hepatitis C Drugs Product Solution and Service
Table 25. Date of Enter into Hepatitis C Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Hepatitis C Drugs Market Size by Type (2015-2020) (Million US$)
Table 28. Global Hepatitis C Drugs Market Size Share by Type (2015-2020)
Table 29. Global Hepatitis C Drugs Revenue Market Share by Type (2021-2026)
Table 30. Global Hepatitis C Drugs Market Size Share by Application (2015-2020)
Table 31. Global Hepatitis C Drugs Market Size by Application (2015-2020) (Million US$)
Table 32. Global Hepatitis C Drugs Market Size Share by Application (2021-2026)
Table 33. North America Key Players Hepatitis C Drugs Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Hepatitis C Drugs Market Share (2019-2020)
Table 35. North America Hepatitis C Drugs Market Size by Type (2015-2020) (Million US$)
Table 36. North America Hepatitis C Drugs Market Share by Type (2015-2020)
Table 37. North America Hepatitis C Drugs Market Size by Application (2015-2020) (Million US$)
Table 38. North America Hepatitis C Drugs Market Share by Application (2015-2020)
Table 39. Europe Key Players Hepatitis C Drugs Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Hepatitis C Drugs Market Share (2019-2020)
Table 41. Europe Hepatitis C Drugs Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Hepatitis C Drugs Market Share by Type (2015-2020)
Table 43. Europe Hepatitis C Drugs Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Hepatitis C Drugs Market Share by Application (2015-2020)
Table 45. China Key Players Hepatitis C Drugs Revenue (2019-2020) (Million US$)
Table 46. China Key Players Hepatitis C Drugs Market Share (2019-2020)
Table 47. China Hepatitis C Drugs Market Size by Type (2015-2020) (Million US$)
Table 48. China Hepatitis C Drugs Market Share by Type (2015-2020)
Table 49. China Hepatitis C Drugs Market Size by Application (2015-2020) (Million US$)
Table 50. China Hepatitis C Drugs Market Share by Application (2015-2020)
Table 51. Japan Key Players Hepatitis C Drugs Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Hepatitis C Drugs Market Share (2019-2020)
Table 53. Japan Hepatitis C Drugs Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Hepatitis C Drugs Market Share by Type (2015-2020)
Table 55. Japan Hepatitis C Drugs Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Hepatitis C Drugs Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Hepatitis C Drugs Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Hepatitis C Drugs Market Share (2019-2020)
Table 59. Southeast Asia Hepatitis C Drugs Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Hepatitis C Drugs Market Share by Type (2015-2020)
Table 61. Southeast Asia Hepatitis C Drugs Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Hepatitis C Drugs Market Share by Application (2015-2020)
Table 63. India Key Players Hepatitis C Drugs Revenue (2019-2020) (Million US$)
Table 64. India Key Players Hepatitis C Drugs Market Share (2019-2020)
Table 65. India Hepatitis C Drugs Market Size by Type (2015-2020) (Million US$)
Table 66. India Hepatitis C Drugs Market Share by Type (2015-2020)
Table 67. India Hepatitis C Drugs Market Size by Application (2015-2020) (Million US$)
Table 68. India Hepatitis C Drugs Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Hepatitis C Drugs Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Hepatitis C Drugs Market Share (2019-2020)
Table 71. Central & South America Hepatitis C Drugs Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Hepatitis C Drugs Market Share by Type (2015-2020)
Table 73. Central & South America Hepatitis C Drugs Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Hepatitis C Drugs Market Share by Application (2015-2020)
Table 75. Gilead sciences Company Details
Table 76. Gilead sciences Business Overview
Table 77. Gilead sciences Product
Table 78. Gilead sciences Revenue in Hepatitis C Drugs Business (2015-2020) (Million US$)
Table 79. Gilead sciences Recent Development
Table 80. Abbvi Company Details
Table 81. Abbvi Business Overview
Table 82. Abbvi Product
Table 83. Abbvi Revenue in Hepatitis C Drugs Business (2015-2020) (Million US$)
Table 84. Abbvi Recent Development
Table 85. Johnson & Johnson Company Details
Table 86. Johnson & Johnson Business Overview
Table 87. Johnson & Johnson Product
Table 88. Johnson & Johnson Revenue in Hepatitis C Drugs Business (2015-2020) (Million US$)
Table 89. Johnson & Johnson Recent Development
Table 90. Merck Company Details
Table 91. Merck Business Overview
Table 92. Merck Product
Table 93. Merck Revenue in Hepatitis C Drugs Business (2015-2020) (Million US$)
Table 94. Merck Recent Development
Table 95. Glaxosmithkline Company Details
Table 96. Glaxosmithkline Business Overview
Table 97. Glaxosmithkline Product
Table 98. Glaxosmithkline Revenue in Hepatitis C Drugs Business (2015-2020) (Million US$)
Table 99. Glaxosmithkline Recent Development
Table 100. Novartis Company Details
Table 101. Novartis Business Overview
Table 102. Novartis Product
Table 103. Novartis Revenue in Hepatitis C Drugs Business (2015-2020) (Million US$)
Table 104. Novartis Recent Development
Table 105. Bristol-Myers Squibb Company Details
Table 106. Bristol-Myers Squibb Business Overview
Table 107. Bristol-Myers Squibb Product
Table 108. Bristol-Myers Squibb Revenue in Hepatitis C Drugs Business (2015-2020) (Million US$)
Table 109. Bristol-Myers Squibb Recent Development
Table 110. Roche Business Overview
Table 111. Roche Product
Table 112. Roche Company Details
Table 113. Roche Revenue in Hepatitis C Drugs Business (2015-2020) (Million US$)
Table 114. Roche Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hepatitis C Drugs Market Share by Type: 2020 VS 2026
Figure 2. Anti-Viral Features
Figure 3. Immuno-modulators Features
Figure 4. Others Features
Figure 5. Global Hepatitis C Drugs Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Hepatitis C Drugs Report Years Considered
Figure 9. Global Hepatitis C Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Hepatitis C Drugs Market Share by Regions: 2020 VS 2026
Figure 11. Global Hepatitis C Drugs Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Hepatitis C Drugs Market Share by Players in 2019
Figure 14. Global Top Hepatitis C Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatitis C Drugs as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Hepatitis C Drugs Revenue in 2019
Figure 16. North America Hepatitis C Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Hepatitis C Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Hepatitis C Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Hepatitis C Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Hepatitis C Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Hepatitis C Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Hepatitis C Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
肝炎治療薬の世界市場（～2026年） Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption…- B型肝炎治療薬の世界市場（～2026年） Market Analysis and Insights: Global Hepatitis B Therapeutics Market The global Hepatitis B Therapeutics market size is projected to reach US$ 2568.8 million by 2026, from US$ 2489 million in 2020, at a CAGR of 3.0%% during 2021-2026. Global Hepatitis B Therapeutics Scope and Market Size Hepatitis B…
- ウイルス性肝炎・レトロウイルス診断検査の世界市場（～2026年） Diagnostics tests for viral hepatitis and retrovirus help in screening, diagnosing, and managing diseases in humans. The tests are usually performed in the laboratory under controlled environment. In hepatitis and retrovirus infections, the diagnostic tests provide a valuable health status of patien…
- 予防的B型肝炎ウイルスワクチンの世界市場（～2026年） The main objective of hepatitis B immunization strategies is to prevent chronic hepatitis B virus infection and its serious consequences, including liver cirrhosis and hepatocellular cancer. The increasing prevalence and incidence of hepatitis B infection is the dominant factor of driving the growth…
- B型肝炎ウイルス（HBV）の世界市場（～2026年） Over the recent years, the global Hepatitis B Treatment industry has been driven by the increasing number of patients diagnosed with Chronic Hepatitis B which results in severe complications, rising awareness about the consequences of viral infection, rigorous efforts to eliminate the viral infectio…